Drug Database
Back to search

Belgium· BE-AMP-SAM235776-00

Mediaven Forte 30 mg

A capillary stabilizing agents product containing naftazone, registered in Belgium by Will Pharma. The same ATC class is registered in 2 of our 19 countries.

ATC C05C

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedMediaven Forte 30 mgATCC05CREGISTER NO.BE-AMP-SAM235776-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about naftazoneAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Naftazone is registered in 2 of 19 countries.

Countries holding a registration under ATC C05C (capillary stabilizing agents), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 2 of them publish a price we can compare per daily dose
Search naftazone products by name

Naftazone · ATC C05C

2 / 19 countries

  • Belgiumprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Naftazone
Manufacturer
Will Pharma
Country
Belgium (BE)
ATC code
C05C
ATC class
CAPILLARY STABILIZING AGENTS
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    2316719
  • be_apb
    2762839

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Naftazone in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All naftazone products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • France · Etioven
  • Luxembourg · Mediaven Forte

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2b90a279-15cc-46c3-84ca-dcb3d0c987fd
GET /v1/drugs/2b90a279-15cc-46c3-84ca-dcb3d0c987fd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Mediaven Forte 30 mg",
  "name_fr": "Mediaven Forte 30 mg",
  "name_nl": "Mediaven Forte 30 mg",
  "amp_code": "SAM235776-00",
  "strengths": [
    "30.0000",
    "18.0000"
  ],
  "pack_count": 2,
  "substances": [
    "Naftazone",
    "Sodium Starch Glycolate (Type A)"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Capillary Stabilizing Agents",
  "authorisation_numbers": [
    "BE235776"
  ]
}
API referenceMCP serverPlans

See everything about naftazone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console